Volitionrx (VNRX) Cash from Financing Activities (2011 - 2025)

Volitionrx has reported Cash from Financing Activities for 15 years, with the latest figure at $6.2 million in Q4 2025.

• For the quarter ending Q4 2025, Cash from Financing Activities rose 168.83% year-over-year to $6.2 million; the trailing twelve-month figure through Dec 2025 stood at $17.1 million (up 97.44% YoY), and the FY2025 full-year result was $17.1 million, up 97.44% from the prior year.
• Cash from Financing Activities for Q4 2025 stood at $6.2 million, up from $1.6 million in the prior quarter.
• The five-year high for Cash from Financing Activities was $20.2 million in Q1 2021, with the low at -$460198.0 in Q2 2022.
• Historically, Cash from Financing Activities has averaged $4.2 million across 5 years, with a median of $2.2 million in 2021.
• The largest YoY upside for Cash from Financing Activities was 13203.23% in 2022 against a maximum downside of 191.81% in 2022.
• Volitionrx's Cash from Financing Activities stood at $2.1 million in 2021, then plunged by 55.85% to $925964.0 in 2022, then jumped by 307.19% to $3.8 million in 2023, then plunged by 39.27% to $2.3 million in 2024, then surged by 168.83% to $6.2 million in 2025.
• The last three Cash from Financing Activities figures came in at $6.2 million (Q4 2025), $1.6 million (Q3 2025), and $5.7 million (Q2 2025), per Business Quant data.